BRCA2 and neoplasm: A three‐drug combination consisting of pyridostatin, NU‐7441 and paclitaxel can effectively suppress growth or even eradicate BRCA1‐ or BRCA2‐deficient tumours and we propose that this triple combination represents an effective therapeutic strategy against BRCA‐mutated cancers.